quavonlimab,lenvatinib,favezelimab,pembrolizumab
eisai,merck
['lenva', 'pembro', 'keynote,495', 'quavonlimab', 'favezelimab', 'imab ']
invited abstract 635 reviews updates on keynote-495 randomized phase 2 in #nsclc with pembro+lenvatinib or quavonlimab or favezelimab. median pfs and os were longer in t cell inf gep nonlow tmb high subgroup #sitc22 